




FIG. 1





FIG. 2

**FIG. 3**

444 ng (18.8 ug/mL in 100% serum) of FI-IFX spiked into sample to outcompete free Infliximab.





FIG. 4




FIG. 5




FIG. 6





FIG. 7



Collection Date	IFX [μg/mL]	ATI [U/mL]	Collection Date	IFX [μg/mL]	ATI [U/mL]
July Year 1	<0.98	12.07	Jan Year 2	<0.98	>150 U/mL
Oct Year 1	<0.98	>150 U/mL	April Year 2	<0.98	>150 U/mL
Nov Year 1	<0.98	>150 U/mL			

FIG. 8




FIG. 9

Collection Date	IFX [µg/mL]	ATI [U/mL]
July Year 1	<0.98	12.07
Oct Year 1	<0.98	>150 U/mL
Nov Year 1	<0.98	>150 U/mL
Jan Year 2	<0.98	>150 U/mL
April Year 2	<0.98	>150 U/mL

Peak area of
TNF532/IFX488 complex
subtracted from Free TNF
area of all samples and
then % of free TNF
calculated




FIG. 10





FIG. 11


Collection Date	IFX [µg/mL]	ATI [U/mL]
Nov Year 1	<0.98	>150 U/mL
Jan Year 2	<0.98	>150 U/mL
April Year 2	<0.98	>150 U/mL

Peak area of
TNF532/IFX488 complex
subtracted from Free TNF
area of all samples and
then % of free TNF
calculated




Rabbit Anti-Human IgG₁ F_c: Non-neutralizing
Ab Control

FIG. 12



ATI Pos. Serum: Mixed Nab/Non-neutralizing
Ab Control

FIG. 13



Purification of ATI from ATI Positive Serum
results in loss of weaker affinity Nab

FIG. 14





FIG. 15

Sample ID	Week #	IFX [µg/mL]	ATI [U/mL]
10113A	7	26.14	17.09
10113B	14	19.26	14.37
10113C	22	17.09	15.12
10113D	30	7.22	10.16




Induction: Weeks 1-14
Maintenance: Weeks 22-50

Peak area of TNF532/IFX488 complex subtracted from all samples and then % of free TNF calculated

FIG. 16

Sample ID	Week #	IFX [µg/mL]	ATI [U/mL]
10509A	22	12.77	11.42
10509B	46	5.63	10.15
10509C	50	27.24	17.57



Induction: Weeks 1-14
Maintenance: Weeks 22-50

Peak area of TNF532/IFX488 complex subtracted from Free TNF area of all samples and then % of free TNF calculated

FIG. 17

Sample ID	Week #	IFX [µg/mL]	ATI [U/mL]
10111	46	8.76	13.59
11505	14	11.42	12.66
11903	60	20.95	11.79
10308	14	1.09	54.64




FIG. 18

Induction: Weeks 1-14
Maintenance: Weeks 22-50

Peak area of TNF532/IFX488 complex subtracted from Free TNF area of all samples and then % of free TNF calculated




FIG. 19






FIG. 20

Patient Study #1 – UC Patient




Collection Date	IFX [μg/mL]	ATI [U/mL]	Confirmed post-vaccination anti-TNF activity
GRD0125	<0.96	>150 U/mL	Yes




Patient will likely not respond to adalimumab

Patient Study #2 – CD Patient





Collection Date	IFX [μg/mL]	ATI [U/mL]	Confirmed post-vaccination anti-TNF activity
PL_CL01956.7	<0.96	356.82 U/mL	Yes



Patient will likely not respond to adalimumab

FIG. 21

Binding (non-NAB) Antibody**Neutralizing Antibody (NAB)****FIG. 22**





FIG. 23



Patient will likely not respond to adalimumab

FIG. 24




FIG. 25




FIG. 26